title: Seven day administration of lamotrigine in epilepsy: placebo-controlled add-on trial.
abstract: A double-blind placebo-controlled trial of 7 days administration of lamotrigine as add-on therapy was performed in 10 patients with frequent therapy-resistant, chiefly partial, seizures. Dosage was adjusted on the basis of estimated half-life. Six patients showed a 50% seizure reduction on lamotrigine and two an increase. Side effects (ataxia, dizziness and apathy) occurred in 3 patients, but only at blood levels above 3 micrograms/ml, and were rapidly relieved when the dose was reduced in two. EEG spike counts were significantly reduced on lamotrigine. There was no evidence of interactions with co-medication.
authors.affiliation: Wellcome Research Laboratories, Beckenham, Kent, U.K.
authors.forename: C D
authors.initials: CD
authors.lastname: Binnie
authors.forename: D J
authors.initials: DJ
authors.lastname: Beintema
authors.forename: R M
authors.initials: RM
authors.lastname: Debets
authors.forename: W
authors.initials: W
authors.lastname: Van Emde Boas
authors.forename: J W
authors.initials: JW
authors.lastname: Meijer
authors.forename: H
authors.initials: H
authors.lastname: Meinardi
authors.forename: A W
authors.initials: AW
authors.lastname: Peck
authors.forename: A M
authors.initials: AM
authors.lastname: Westendorp
authors.forename: W C
authors.initials: WC
authors.lastname: Yuen
mesh_terms: D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004569:Electroencephalography; D004827:Epilepsy / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000077213:Lamotrigine; D008875:Middle Aged; D010919:Placebos; D014227:Triazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D010919:Placebos; D014227:Triazines; D000077213:Lamotrigine